These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 16225632

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Severe mucocutaneous Behcet's disease treated with dexamethasone pulse.
    Verma KK, Tejasvi T, Verma K, Sethuraman G, Bansal A.
    J Assoc Physicians India; 2005 Nov; 53():998-9. PubMed ID: 16515246
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Therapeutic Hotline. Oral allicin in the treatment of Behcet's disease through attenuating oxidative stress: A pilot study in 20 patients with mucocutaneous lesions.
    Zhong J, Xian D, Xiong X, Liu J.
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723197
    [Abstract] [Full Text] [Related]

  • 26. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete.
    Olivieri I, Latanza L, Siringo S, Peruz G, Di Iorio V.
    J Rheumatol; 2008 May; 35(5):930-2. PubMed ID: 18464316
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P, D'Angelo S, Angela P, Coniglio G, Olivieri I.
    Clin Exp Rheumatol; 2010 May; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Behçet's disease: treatment of mucocutaneous lesions.
    Alpsoy E.
    Clin Exp Rheumatol; 2005 May; 23(4):532-9. PubMed ID: 16095126
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy.
    Olivieri I, Padula A, Leccese P, D'Angelo S, Giasi V.
    J Rheumatol; 2009 Apr; 36(4):855. PubMed ID: 19342728
    [No Abstract] [Full Text] [Related]

  • 35. Successful treatment of Behçet's disease with lenalidomide.
    Green J, Upjohn E, McCormack C, Zeldis J, Prince HM.
    Br J Dermatol; 2008 Jan; 158(1):197-8. PubMed ID: 17986298
    [No Abstract] [Full Text] [Related]

  • 36. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.
    Arayssi T, Hamra R, Homeidan F, Uthman I, Awwad ST, Mroue K, Mansour W, Bashshur ZF.
    Clin Exp Rheumatol; 2005 Jan; 23(3):427. PubMed ID: 15971438
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Infliximab as an alternative treatment for Behçet disease when other therapies fail.
    Ugras M, Ertem D, Celikel C, Pehlivanoglu E.
    J Pediatr Gastroenterol Nutr; 2008 Feb; 46(2):212-5. PubMed ID: 18223383
    [No Abstract] [Full Text] [Related]

  • 39. Neonatal Behçet's disease without maternal history.
    Chang YS, Yang YH, Chiang BL.
    Clin Rheumatol; 2011 Dec; 30(12):1641-5. PubMed ID: 21870036
    [Abstract] [Full Text] [Related]

  • 40. Behçet's disease.
    Yesudian PD, Edirisinghe DN, O'Mahony C.
    Int J STD AIDS; 2007 Apr; 18(4):221-7. PubMed ID: 17509169
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.